Ischemic Brain Injury After Intracerebral Hemorrhage
2012; Lippincott Williams & Wilkins; Volume: 43; Issue: 8 Linguagem: Inglês
10.1161/strokeaha.112.655910
ISSN1524-4628
AutoresShyam Prabhakaran, Andrew M. Naidech,
Tópico(s)Neurosurgical Procedures and Complications
ResumoHomeStrokeVol. 43, No. 8Ischemic Brain Injury After Intracerebral Hemorrhage Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissionsDownload Articles + Supplements ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toSupplemental MaterialFree AccessReview ArticlePDF/EPUBIschemic Brain Injury After Intracerebral HemorrhageA Critical Review Shyam Prabhakaran, MD, MS and Andrew M. Naidech, MD, MSPH Shyam PrabhakaranShyam Prabhakaran From Department of Neurology, Northwestern University-Feinberg School of Medicine, Chicago, IL. and Andrew M. NaidechAndrew M. Naidech From Department of Neurology, Northwestern University-Feinberg School of Medicine, Chicago, IL. Originally published19 Jul 2012https://doi.org/10.1161/STROKEAHA.112.655910Stroke. 2012;43:2258–2263Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: January 1, 2012: Previous Version 1 IntroductionIntracerebral hemorrhage (ICH) is the second most common cause of stroke and accounts for 8% to 15% of strokes in Western societies with an estimated incidence of 10 to 25 per 100 000 persons.1–3 Despite advances in the field of stroke and neurocritical care,4 the 30-day mortality has not changed significantly over the past 20 years.3 Indeed, ICH has the highest rates of dependence or death among stroke types and proven treatments are lacking.Clinical trials aimed at limiting hemorrhage growth, procoagulant agents for hemostasis,5 and surgical evacuation6 have not translated into improved clinical outcomes. Antihypertensive therapy for the purpose of reducing hematoma growth has been a mainstay of acute management. Guidelines recommend maintaining mean arterial pressure 2BP-loweringLeukoaraiosisICH volumeHTN etiologyTotal MBs1 mo: prior strokeBaseline MBBaseline DWIDWI indicates diffusion weighted imaging; ICH, intracerebral hemorrhage; MB, microbleeds; CAA, cerebral amyloid angiopathy; HTN, hypertension; BP, blood pressure; IVH, intraventricular hemorrhage.Download figureDownload PowerPointFigure 2. A multihit hypothesis for development of brain ischemia after intracerebral hemorrhage.BP-LoweringThree studies10,30,31 have independently suggested a relationship between degree of BP-lowering and DWI lesions, whereas 2 have not found an association.27,28 In the positive studies, change in BP, in absolute and relative terms, correlated with presence of DWI lesions. This relationship may be heightened in the first few hours after BP treatment (Figure 3).Download figureDownload PowerPointFigure 3. Systolic blood pressure on the y-axis among those with DWI (red) and without DWI lesions (blue) with time in hours from presentation on the x-axis. DWI indicates diffusion-weighted imaging.Cerebral blood flow is regulated across a wide range of mean arterial pressure or cerebral perfusion pressure in the normal state. Cerebral autoregulation is right-shifted in chronic hypertension and may be lost in the setting of acute brain injury such that cerebral blood flow responds linearly to cerebral perfusion pressure.32 Aggressive BP reductions beyond the lower limits of cerebral autoregulation, therefore, have the potential of inducing cerebral ischemia. Elevated ICP and use of vasoactive substances with the potential of exacerbating ICP may further compromise cerebral perfusion pressure in patients with ICH.Cerebral MicroangiopathyFive of the studies consistently reported an association with either microhemorrhage burden on gradient-echo imaging or white matter hyperintensity burden on fluid-attenuated inversion recovery sequences.27–30 A history of stroke was associated with DWI lesions in another study.31 As markers of chronic cerebral vasculopathy, these factors may identify those with significant pre-existing cerebrovascular disease and who are more prone to ischemic injury after ICH.Ischemic stroke and ICH share many risk factors and pathological substrates. The characteristic locations of hypertensive ICH include the basal ganglia, thalamus, pons, and cerebellum, many of which are common sites for lacunar ischemic infarction. They also share many vascular risk factors including hypertension, diabetes mellitus, dyslipidemia, and smoking.33 It is well established that these risk factors lead to distinct pathologies affecting arterioles (typically perforators) including fibrinoid changes, lipohyalinosis, necrosis, and microaneurysm formation. These changes can predispose them to occlusion and/or rupture.34 Further evidence of the link between ischemic stroke and ICH is drawn from the observations that patients surviving ICH have comparable risks for subsequent ischemic and hemorrhagic stroke.35,36In contrast to hypertensive vasculopathy, which affects the deep and subcortical arterioles, CAA affects small superficial and leptomeningeal arterioles. Beta-amyloid protein deposition in these vessel walls leads to degenerative changes that predispose them to vessel fragility and rupture.37 Just as hypertensive vasculopathy can manifest as ICH, ischemic infarction, leukoaraiosis, and vascular dementia, patients harboring CAA pathology can have multiple cerebrovascular presentations including ICH, vasculitis and ischemic stroke, leukoencephalopathy, and dementia.38 Indeed, white matter disease is increased and cerebral blood flow responses are impaired in patients with CAA compared with control subjects.39,40Thus, a chronic microangiopathy, either due to hypertension or CAA, may pre-exist in many patients with ICH. These underlying disease processes may place such patients at risk for both ischemic and hemorrhagic stroke. Vascular biological substrates may also play critical roles in determining the response to hemodynamic alternations after ICH and precipitate secondary ischemic injury. For instance, pre-existing microvascular flow impairment may be exacerbated by aggressive BP-lowering and/or thrombotic activation after ICH and result in small ischemic infarcts.Further support of an underlying microangiopathy in both hemorrhagic and ischemic stroke comes from a recent report of subclinical incident microhemorrhage occurrence (unrelated to hemorrhagic transformation) after acute ischemic stroke. In a serial brain MRI study of 237 patients with ischemic stroke, 12.7% of patients developed new microhemorrhages within days of the initial scan.41 A common microvascular disarray might underlie both hemorrhagic and ischemic stroke and promote a "stroke-prone state" after any acute cerebrovascular insult.24 These may be mediated by endothelial dysfunction, active inflammation, and breakdown of the blood–brain barrier in ICH.42 We, therefore, speculate that hypertensive and CAA-mediated changes in the microvasculature lead to hemorrhagic or ischemic stroke in isolation in most patients but can occur in rapid sequence or simultaneously in some patients.Other Mechanisms and Provoking FactorsAs noted, ICP elevation in moderate- or large-volume hemorrhages or those associated with intraventricular hemorrhage and hydrocephalus may lower the threshold for ischemia in the setting of relatively modest but rapid BP-lowering. Volume of ICH and intraventricular extension, probably as surrogate markers of ICP, have been associated with DWI lesions.30,31 Alternatively, many patients with ICH with vascular risk factors may ingest antithrombotic agents and harbor large-artery stenosis or cardiac sources of embolism at baseline. Thus, ischemic stroke may simply be occurring in high-risk patients in the setting of antiplatelet therapy withdrawal.43Another possibility is that frank hemorrhagic transformation of an embolic ischemic stroke may be misdiagnosed as spontaneous ICH with remote DWI lesions providing evidence of embolism. This would unlikely explain such a large proportion of patients with this finding, however. Other unlikely mechanisms include local vascular compression due to the mass effect from the hematoma. A small percentage of patients also undergo craniotomy, during which low BPs, anesthetic agents, manipulation of arteries, and thrombotic activation with surgery may promote ischemia. Vasospasm, which is common after subarachnoid hemorrhage, is not known to occur after spontaneous ICH in the absence of an unusual amount of subarachnoid blood or a reversible vasculopathy that may present with ischemic and hemorrhagic stroke (ie, Call-Fleming or reversible cerebral vasoconstriction syndrome). Finally, given the delayed incident lesions at 1 month, there may be a period of thrombotic or inflammatory activation that leads to subclinical and clinical events soon after ICH, like in other acute brain injury states. In animal models of subarachnoid hemorrhage44 and traumatic brain injury,45 platelets have been shown to aggregate and cause mircrovascular occlusion due to an inflammatory prothrombotic environment.Impact on Long-Term OutcomesGiven the data on the prevalence of ischemic lesions after ICH, the next logical question is: do they matter? Silent brain infarcts are frequently observed on brain imaging of elderly individuals, serve as markers for the extent or severity of cerebrovascular disease, and predict subsequent risk of stroke and vascular dementia.46–48 Early subclinical DWI lesions after acute ischemic stroke also increase the subsequent risk of recurrent ischemic stroke, transient ischemic attack, and vascular death.49 Silent infarcts may also interact with the index infarct volume and worsen the degree of motor impairment in patients with stroke.50Two longitudinal studies have evaluated the influence of DWI lesions on subsequent functional outcomes after ICH. At 3 months, those with DWI lesions were 5-fold more likely to have poor functional outcomes (defined as modified Rankin Scale score 4–6 indicating dependence or death) adjusting for known predictors (age, initial stroke severity, and ICH score).10 Another single-center study evaluated outcomes at 1 year and noted that those with DWI lesions were >6-fold more likely to have poor outcomes at follow-up than those without, independent of stroke severity.51 A third prospective study of 97 patients with ICH followed for median 42 months demonstrated that DWI lesions significantly increased risks of ischemic stroke and combined ischemic stroke, ICH, and vascular death.28The mechanisms by which small ischemic lesions worsen outcome after ICH are uncertain. These may reduce neuroplasticity and retard restorative ipsi- and contralesional synaptic networks. Some lesions may be strategically symptomatic but only become recognized after the initial clinical presentation, influenced mostly by the hematoma itself, recedes in the subacute period. Lastly, DWI lesions in ICH may simply be markers for "frail" patients who are destined for poor recovery and elevated risk of recurrent stroke.Implications for Current PracticeThese studies cumulatively support (1) a considerable (approximately 25%) prevalence of DWI lesions; (2) a strong correlation with BP-lowering; and (3) a negative impact of DWI lesions on functional outcomes after ICH. Thus, it may be time to reconsider our approach to this disease and to re-evaluate ongoing clinical trials aimed at BP-lowering after ICH. Aggressive BP-lowering has become standard practice at many centers at the time the pivotal clinical trials to determine its clinical impact are still underway; a more refined approach with careful titration of antihypertensive therapy and using individualized targets may be necessary. Randomized clinical trials of BP-lowering should incorporate MRI to evaluate for secondary ischemic lesions and assess their influence on functional outcomes. We postulate that DWI lesions may modify the effect of BP-lowering on functional outcomes after ICH such that it may be hazardous in those with DWI lesions and beneficial in those without.Future DirectionsGiven these potential implications and yet many open questions, it is imperative that research in this area continue. First, imaging techniques including perfusion and functional imaging may help quantify the hemodynamic effects of acute BP-lowering after ICH and evaluate the impact of "silent" lesions on functional recovery. Second, serial MRI studies are needed to define the timing of ischemic lesions because subacute infarcts may be amenable to prevention. Third, detailed outcomes assessments are currently lacking but would provide insights into subtle cognitive or quality-of-life effects not appreciated by crude outcome measures such as the Rankin Scale. Fourth, pilot studies should assess the prevalence of DWI lesions at different target BP levels and the safety of ischemic stroke prevention strategies such as aspirin and statin therapy after ICH.New targets for therapeutic intervention in ICH are sorely needed. Current guidelines for BP reduction and hemostatic therapy to limit hematoma growth at the possible expense of cerebral hypoperfusion and arterial thrombosis, respectively, may be doing more harm than good. If an active biological link between hemorrhagic and ischemic brain disease exists and imaging-based techniques can identify those at risk for either or both conditions, then the relative value of secondary prevention strategies such as lipid-lowering, long-term BP control, glycemic regulation, and antithrombotic agents gains even greater importance for individualized application in vulnerable patients. Early use of antiplatelet and statin therapies to prevent secondary neuronal injury during a proinflammatory, "stroke-prone" period even at the expense of hemorrhage growth or recurrent hemorrhage may be more beneficial than currently believed. Furthermore, risk factors such as carotid artery stenosis, atrial fibrillation, and underlying hypercoagulable states may need to be considered in the diagnostic evaluation of ICH. In summary, the emerging data on secondary brain ischemia after ICH may offer a novel therapeutic target for this deadly disease.Source of FundingSupported by American Heart Association Midwest Affiliate Grant 11CRP7520073 (S.P.).DisclosuresNone.FootnotesCorrespondence to Shyam Prabhakaran, MD, MS, 710 N Lakeshore Drive, Suite 1417, Chicago, IL 60611. E-mail shyam.[email protected]eduReferences1. Broderick JP, Brott T, Tomsick T, Miller R, Huster G. Intracerebral hemorrhage more than twice as common as subarachnoid hemorrhage. J Neurosurg. 1993; 78: 188– 191. CrossrefMedlineGoogle Scholar2. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009; 8: 355– 369. CrossrefMedlineGoogle Scholar3. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010; 9: 167– 176. CrossrefMedlineGoogle Scholar4. Diringer MN, Edwards DF. Admission to a neurologic/neurosurgical intensive care unit is associated with reduced mortality rate after intracerebral hemorrhage. Crit Care Med. 2001; 29: 635– 640. CrossrefMedlineGoogle Scholar5. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN , et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008; 358: 2127– 2137. CrossrefMedlineGoogle Scholar6. Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT , et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the international surgical trial in intracerebral haemorrhage (STICH): a randomised trial. Lancet. 2005; 365: 387– 397. CrossrefMedlineGoogle Scholar7. Morgenstern LB, Hemphill JC, Anderson C, Becker K, Broderick JP, Connolly ES , et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010; 41: 2108– 2129. LinkGoogle Scholar8. Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B , et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol. 2008; 7: 391– 399. CrossrefMedlineGoogle Scholar9. Qureshi AI, Palesch YY, Martin R, Novitzke J, Cruz-Flores S, Ehtisham A , et al. Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage: results from the antihypertensive treatment of acute cerebral hemorrhage study. Arch Neurol. 2010; 67: 570– 576. CrossrefMedlineGoogle Scholar10. Garg RK, Liebling SM, Maas MB, Nemeth AJ, Russell EJ, Naidech AM. Blood pressure reduction, decreased diffusion on MRI, and outcomes after intracerebral hemorrhage. Stroke. 2012; 43: 67– 71. LinkGoogle Scholar11. Kang BK, Na DG, Ryoo JW, Byun HS, Roh HG, Pyeun YS. Diffusion-weighted MR imaging of intracerebral hemorrhage. Korean J Radiol. 2001; 2: 183– 191. CrossrefMedlineGoogle Scholar12. Carhuapoma JR, Wang PY, Beauchamp NJ, Keyl PM, Hanley DF, Barker PB. Diffusion-weighted MRI and proton MR spectroscopic imaging in the study of secondary neuronal injury after intracerebral hemorrhage. Stroke. 2000; 31: 726– 732. LinkGoogle Scholar13. Herweh C, Juttler E, Schellinger PD, Klotz E, Jenetzky E, Orakcioglu B , et al. Evidence against a perihemorrhagic penumbra provided by perfusion computed tomography. Stroke. 2007; 38: 2941– 2947. LinkGoogle Scholar14. Kidwell CS, Saver JL, Mattiello J, Warach S, Liebeskind DS, Starkman S , et al. Diffusion-perfusion MR evaluation of perihematomal injury in hyperacute intracerebral hemorrhage. Neurology. 2001; 57: 1611– 1617. CrossrefMedlineGoogle Scholar15. Mayer SA, Lignelli A, Fink ME, Kessler DB, Thomas CE, Swarup R , et al. Perilesional blood flow and edema formation in acute intracerebral hemorrhage: a SPECT study. Stroke. 1998; 29: 1791– 1798. LinkGoogle Scholar16. Powers WJ, Zazulia AR, Videen TO, Adams RE, Yundt KD, Aiyagari V , et al. Autoregulation of cerebral blood flow surrounding acute (6 to 22 hours) intracerebral hemorrhage. Neurology. 2001; 57: 18– 24. CrossrefMedlineGoogle Scholar17. Schellinger PD, Fiebach JB, Hoffmann K, Becker K, Orakcioglu B, Kollmar R , et al. Stroke MRI in intracerebral hemorrhage: is there a perihemorrhagic penumbra?Stroke. 2003; 34: 1674– 1679. LinkGoogle Scholar18. Zazulia AR, Diringer MN, Videen TO, Adams RE, Yundt K, Aiyagari V , et al. Hypoperfusion without ischemia surrounding acute intracerebral hemorrhage. J Cereb Blood Flow Metab. 2001; 21: 804– 810. CrossrefMedlineGoogle Scholar19. Butcher KS, Baird T, MacGregor L, Desmond P, Tress B, Davis S. Perihematomal edema in primary intracerebral hemorrhage is plasma derived. Stroke. 2004; 35: 1879– 1885. LinkGoogle Scholar20. Kuwata N, Kuroda K, Funayama M, Sato N, Kubo N, Ogawa A. Dysautoregulation in patients with hypertensive intracerebral hemorrhage. A SPECT study. Neurosurg Rev. 1995; 18: 237– 245. CrossrefMedlineGoogle Scholar21. von Helden A, Schneider GH, Unterberg A, Lanksch WR. Monitoring of jugular venous oxygen saturation in comatose patients with subarachnoid haemorrhage and intracerebral haematomas. Acta Neurochir Suppl (Wien). 1993; 59: 102– 106. MedlineGoogle Scholar22. Qureshi AI, Hanel RA, Kirmani JF, Yahia AM, Hopkins LN. Cerebral blood flow changes associated with intracerebral hemorrhage. Neurosurg Clin N Am. 2002; 13: 355– 370. CrossrefMedlineGoogle Scholar23. Lovblad KO, Laubach HJ, Baird AE, Curtin F, Schlaug G, Edelman RR , et al. Clinical experience with diffusion-weighted MR in patients with acute stroke. AJNR Am J Neuroradiol. 1998; 19: 1061– 1066. MedlineGoogle Scholar24. Kang DW, Latour LL, Chalela JA, Dambrosia JA, Warach S. Early and late recurrence of ischemic lesion on MRI: evidence for a prolonged stroke-prone state?Neurology. 2004; 63: 2261– 2265. CrossrefMedlineGoogle Scholar25. Coutts SB, Hill MD, Simon JE, Sohn CH, Scott JN, Demchuk AM. Silent ischemia in minor stroke and TIA patients identified on MR imaging. Neurology. 2005; 65: 513– 517. CrossrefMedlineGoogle Scholar26. Wartenberg KE, Sheth SJ, Schmidt MJ, Frontera JA, Rincon F, Ostapkovich N , et al. Acute ischemic injury on diffusion-weighted magnetic resonance imaging after poor grade subarachnoid hemorrhage. Neurocrit Care. 2011; 14: 407– 415. CrossrefMedlineGoogle Scholar27. Gregoire SM, Charidimou A, Gadapa N, Dolan E, Antoun N, Peeters A , et al. Acute ischaemic brain lesions in intracerebral haemorrhage: multicentre cross-sectional magnetic resonance imaging study. Brain. 2011; 134: 2376– 2386. CrossrefMedlineGoogle Scholar28. Kang DW, Han MK, Kim HJ, Yun SC, Jeon SB, Bae HJ , et al. New ischemic lesions coexisting with acute intracerebral hemorrhage. Neurology. (in press).Google Scholar29. Kimberly WT, Gilson A, Rost NS, Rosand J, Viswanathan A, Smith EE , et al. Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Neurology. 2009; 72: 1230– 1235. CrossrefMedlineGoogle Scholar30. Menon RS, Burgess RE, Wing JJ, Gibbons MC, Shara NM, Fernandez S , et al. Predictors of highly prevalent brain ischemia in intracerebral hemorrhage. Ann Neurol. 2012; 199– 205.CrossrefMedlineGoogle Scholar31. Prabhakaran S, Gupta R, Ouyang B, John S, Temes RE, Mohammad Y , et al. Acute brain infarcts after spontaneous intracerebral hemorrhage: a diffusion-weighted imaging study. Stroke. 2010; 41: 89– 94. LinkGoogle Scholar32. Paulson OB, Waldemar G, Schmidt JF, Strandgaard S. Cerebral circulation under normal and pathologic conditions. Am J Cardiol. 1989; 63: 2C– 5C. CrossrefMedlineGoogle Scholar33. Zia E, Pessah-Rasmussen H, Khan FA, Norrving B, Janzon L, Berglund G , et al. Risk factors for primary intracerebral hemorrhage: a population-based nested case–control study. Cerebrovasc Dis. 2006; 21: 18– 25. CrossrefMedlineGoogle Scholar34. Plesea IE, Camenita A, Georgescu CC, Enache SD, Zaharia B, Georgescu CV , et al. Study of cerebral vascular structures in hypertensive intracerebral haemorrhage. Rom J Morphol Embryol. 2005; 46: 249– 256. MedlineGoogle Scholar35. Hill MD, Silver FL, Austin PC, Tu JV. Rate of stroke recurrence in patients with primary intracerebral hemorrhage. Stroke. 2000; 31: 123– 127. LinkGoogle Scholar36. Zia E, Engstrom G, Svensson PJ, Norrving B, Pessah-Rasmussen H. Three-year survival and stroke recurrence rates in patients with primary intracerebral hemorrhage. Stroke. 2009; 40: 3567– 3573. LinkGoogle Scholar37. Smith EE, Greenberg SM. Beta-amyloid, blood vessels, and brain function. Stroke. 2009; 40: 2601– 2606. LinkGoogle Scholar38. Maia LF, Mackenzie IR, Feldman HH. Clinical phenotypes of cerebral amyloid angiopathy. J Neurol Sci. 2007; 257: 23– 30. CrossrefMedlineGoogle Scholar39. Smith EE, Gurol ME, Eng JA, Engel CR, Nguyen TN, Rosand J , et al. White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage. Neurology. 2004; 63: 1606– 1612. CrossrefMedlineGoogle Scholar40. Smith EE, Vijayappa M, Lima F, Delgado P, Wendell L, Rosand J , et al. Impaired visual evoked flow velocity response in cerebral amyloid angiopathy. Neurology. 2008; 71: 1424– 1430. CrossrefMedlineGoogle Scholar41. Jeon SB, Kwon SU, Cho AH, Yun SC, Kim JS, Kang DW. Rapid appearance of new cerebral microbleeds after acute ischemic stroke. Neurology. 2009; 73: 1638– 1644. CrossrefMedlineGoogle Scholar42. Kidwell CS, Burgess R, Menon R, Warach S, Latour LL. Hyperacute injury marker (HARM) in primary hemorrhage: a distinct form of CNS barrier disruption. Neurology. 2011; 77: 1725– 1728. CrossrefMedlineGoogle Schola
Referência(s)